查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070562

製藥業品管及合規市場規模、佔有率、成長、全球產業分析、區域趨勢及 2026-2034 年預測。

Pharma Quality Control and Compliance Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 198 Pages | 商品交期: 2-3個工作天內

價格

推動醫藥品管和合規市場成長要素

2025年全球藥品品管和合規市場規模為107.9億美元，預計將從2026年的115.8億美元成長到2034年的228.2億美元，預測期內複合年成長率為8.85%。北美市場佔主導地位，預計2025年市場佔有率將達到38.27%，這得益於其強大的藥品生產基地、先進的品管基礎設施和嚴格的法規結構。

藥品品管和合規解決方案對於確保藥品在整個生產過程中的安全性、有效性和法規合規性至關重要。這些系統支援原料檢測、微生物分析、批次放行程序、穩定性測試、GMP合規性、驗證活動和文件管理。生物製藥、疫苗、細胞療法和基因療法生產日益複雜，正推動對先進品管技術和合規平台的大量投資。

市場規模及預測

年度市場規模（十億美元）

2025年10.79

2026年11月58日

2034 22.82

市場擴張的促進因素包括藥品產量增加、監管更加嚴格以及數位化品管系統的日益普及。

市場趨勢

擴大自動化合規解決方案的應用

製藥業品管和合規市場最顯著的趨勢之一是從傳統的紙本品管系統向自動化數位平台的轉變。製藥公司正擴大採用電子品管系統 (eQMS)、實驗室資訊管理系統 (LIMS)、人工智慧驅動的合規工具和數位化批次放行平台。

這些技術能夠提升可追溯性，減少文件錯誤，增強稽核應對力，並強化整個製造流程的資料完整性。 2025年1月，Honeywell推出了TrackWise生命科學平台，旨在透過先進的自動化和數位轉型，幫助生命科學公司整合製造和品管。

市場促進因素

藥物研發活動增加

醫藥和生技產品線的快速擴張是市場需求的主要驅動力。新藥研發專案需要進行廣泛的品質檢測、穩定性測試、微生物評估、驗證活動以及法規文件編制。

隨著企業在生物製藥、疫苗和先進療法領域的研發和生產活動不斷擴大，對精密品管系統的需求也日益成長。 2025年4月，諾華宣布計劃投資230億美元，用於擴建其在美國的生產和研發基礎設施，凸顯了其對以品質為中心的生產能力的日益重視。

市場限制因素

嚴格的監管要求

監管合規仍然是製藥生產中最具挑戰性的方面之一。企業必須持續投資於經過驗證的系統、品質監控程序、員工培訓、污染預防措施和文件記錄，以滿足全球監管機構的要求。

不遵守相關法規可能導致警告信、產品核可延誤、糾正措施相關成本以及營運中斷。這些法規的複雜性對小規模製造商和跨地區營運的公司構成了特殊的挑戰。

市場機遇

擴大品管服務外包規模

品管服務外包的日益普及帶來了巨大的成長機會。製藥企業正擴大與專業檢測實驗室和合規服務供應商合作，以提高效率並降低營運成本。

查爾斯河實驗室和歐陸科學等機構提供符合 GMP 標準的檢測服務，幫助製藥公司管理複雜的分析要求，同時維持合規性。

市場挑戰

維持全球品質標準的一致性

隨著企業從多個國家原料藥（API）、輔料、包裝材料和生產服務，全球醫藥供應鏈變得日益複雜。如何確保供應商和製造地之間品質標準的一致性仍然是一項重大挑戰。

供應商之間品管系統、文件規格和測試程序的差異增加了合規風險，需要對供應商審核、數位化品管平台和全球監控計畫進行大量投資。

細分分析

透過提供的內容

預計到2025年，產品細分市場將成為市場成長的主要驅動力，這主要得益於製藥檢測和品質保證操作中設備和耗材的廣泛應用。層析法系統、微生物檢測設備、過濾器、試劑和監測儀器在符合GMP規範的生產中仍然至關重要。

隨著基於雲端的品管和合規平台的普及，軟體領域預計將經歷最快的成長。

用途別

由於小分子藥物的全球產量高，且對分析測試、穩定性測試和批次放行等活動的需求持續存在，因此小分子藥物領域佔了最大的市場佔有率。預計到2026年，該領域將佔市場佔有率的54.3%。

按功能

預計到 2025 年，成品檢測和批次放行領域將成為市場驅動力，並在 2026 年佔 21.3% 的市場佔有率。這項能力對於整體合規運作至關重要，因為所有藥品批次在上市前都必須經過全面的品質檢驗。

最終用戶

預計到 2025 年，製藥和生物技術公司將佔最大的市場佔有率，並在 2026 年保持 71.4% 的市場佔有率。這些組織仍然是品管(QC) 設備、軟體平台、驗證工具和合規服務的最大買家。

區域分析

北美洲

預計北美將引領市場，到 2025 年市場規模將達到 41.3 億美元。該地區憑藉其在先進的製藥生產設施、強力的監管執法以及對品質保證技術的大量投資方面的優勢，佔市場主導地位。

歐洲

預計歐洲在預測期內將以7.90%的複合年成長率成長。強大的生物製藥生產能力和完善的GMP標準將繼續支撐該地區的成長。

亞太地區

預計亞太地區將成為成長最快的地區，到 2026 年將達到 27.6 億美元。中國和印度製藥業的快速擴張正在推動對品管(QC) 實驗室、污染預防系統和法規遵循解決方案的投資增加。

拉丁美洲、中東和非洲

由於當地藥品產量增加、法規結構加強以及人們越來越重視減少對進口藥品的依賴，預計這些地區將經歷適度成長。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 製藥業品管和合規的技術進步
  • 主要產業趨勢（合併、收購、合作等）
  • 新產品發布：按主要公司分類
  • 主要國家和地區的監管趨勢

第5章：2021-2034年全球製藥業品管與合規市場分析、洞察與預測

  • 市場分析、洞察與預測：按產品/服務分類。
    • 軟體
    • 服務
  • 市場分析、洞察與預測：按應用領域分類
    • 小分子藥物
    • 生物製劑和生物相似藥
    • 疫苗
    • 細胞和基因治療
    • 其他
  • 市場分析、洞察與預測：按功能分類
    • 原料品管
    • 微生物學和污染控制
    • 穩定性和保存期限測試
    • 進程內品管
    • 最終產品測試和批次放行
    • 監理合規管理
    • 驗證與確認/品質系統管理
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 製藥和生物技術公司
    • CRO／CDMO
    • 其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美製藥業品管與合規市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：2021-2034年歐洲製藥業品管與合規市場分析、洞察與預測

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太製藥產業品管與合規市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲製藥產業品管與合規市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東與非洲製藥產業品管與合規市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies, Inc.
    • Waters Corporation
    • Veeva Systems
    • Honeywell International Inc.
    • Sartorius AG
    • Charles River Laboratories
    • Eurofins Scientific
    • LabVantage Solutions Inc.
    • LabWare
Product Code: FBI116093

Growth Factors of pharma quality control and compliance Market

The global pharma quality control and compliance market was valued at USD 10.79 billion in 2025 and is projected to grow from USD 11.58 billion in 2026 to USD 22.82 billion by 2034, registering a CAGR of 8.85% during the forecast period. North America dominated the market with a 38.27% share in 2025, supported by its strong pharmaceutical manufacturing base, advanced quality management infrastructure, and stringent regulatory framework.

Pharma quality control and compliance solutions are critical for ensuring drug safety, efficacy, and regulatory adherence throughout the pharmaceutical manufacturing process. These systems support raw material testing, microbiological analysis, batch-release procedures, stability studies, GMP compliance, validation activities, and documentation management. Increasing manufacturing complexity in biologics, vaccines, cell therapies, and gene therapies is driving substantial investments in advanced quality control technologies and compliance platforms.

Market Size and Forecast

Year Market Value (USD Billion)

2025 10.79

2026 11.58

2034 22.82

The market's expansion is fueled by rising pharmaceutical production, growing regulatory scrutiny, and increasing adoption of digital quality management systems.

Market Trends

Growing Adoption of Automated Compliance Solutions

One of the most prominent trends in the pharma quality control and compliance market is the shift from traditional paper-based quality systems toward automated digital platforms. Pharmaceutical companies are increasingly implementing electronic Quality Management Systems (eQMS), Laboratory Information Management Systems (LIMS), AI-enabled compliance tools, and digital batch-release platforms.

These technologies enhance traceability, reduce documentation errors, improve audit readiness, and strengthen data integrity across manufacturing operations. In January 2025, Honeywell launched the TrackWise Life Sciences Platform to help life sciences companies integrate manufacturing and quality management through advanced automation and digital transformation.

Market Drivers

Increasing Drug Development Activities

The rapid growth of pharmaceutical and biotechnology pipelines is a major factor driving market demand. New drug development programs require extensive quality testing, stability studies, microbiological assessments, validation activities, and regulatory documentation.

As companies expand research and manufacturing activities for biologics, vaccines, and advanced therapies, the need for sophisticated quality control systems continues to rise. In April 2025, Novartis announced plans to invest USD 23 billion in expanding its U.S. manufacturing and R&D infrastructure, highlighting the growing focus on quality-focused production capabilities.

Market Restraints

Stringent Regulatory Requirements

Regulatory compliance remains one of the most challenging aspects of pharmaceutical manufacturing. Companies must continuously invest in validated systems, quality oversight programs, employee training, contamination control measures, and documentation management to satisfy global regulatory agencies.

Failure to comply can result in warning letters, delayed product approvals, remediation expenses, and operational disruptions. Regulatory complexity is particularly challenging for small manufacturers and companies operating across multiple regions.

Market Opportunities

Expansion of Outsourced Quality Control Services

The increasing use of outsourced quality control services presents significant growth opportunities. Pharmaceutical manufacturers are increasingly partnering with specialized testing laboratories and compliance service providers to improve efficiency and reduce operational costs.

Organizations such as Charles River Laboratories and Eurofins Scientific offer GMP-certified testing services that help pharmaceutical companies manage complex analytical requirements while maintaining regulatory compliance.

Market Challenges

Maintaining Consistent Global Quality Standards

Global pharmaceutical supply chains continue to become more complex as companies source APIs, excipients, packaging materials, and manufacturing services from multiple countries. Maintaining uniform quality standards across suppliers and manufacturing sites remains a major challenge.

Variations in supplier quality systems, documentation practices, and testing procedures increase compliance risks and require significant investments in supplier audits, digital quality platforms, and global oversight programs.

Segmentation Analysis

By Offering

The products segment dominated the market in 2025 due to the extensive use of instruments and consumables in pharmaceutical testing and quality assurance operations. Chromatography systems, microbiological testing equipment, filters, reagents, and monitoring instruments remain essential for GMP-compliant manufacturing.

The software segment is projected to witness the fastest growth with increasing adoption of cloud-based quality management and compliance platforms.

By Application

The small molecule drugs segment held the largest market share owing to extensive global manufacturing volumes and continuous demand for analytical testing, stability studies, and batch-release activities. The segment is expected to account for 54.3% of the market in 2026.

By Function

The finished product testing and batch release segment dominated the market in 2025 and is projected to hold 21.3% market share in 2026. Every pharmaceutical batch must undergo comprehensive quality verification before commercial release, making this function critical to overall compliance operations.

By End User

The pharmaceutical and biotechnology companies segment accounted for the largest market share in 2025 and is expected to maintain 71.4% share in 2026. These organizations remain the largest purchasers of QC instruments, software platforms, validation tools, and compliance services.

Regional Analysis

North America

North America led the market with a value of USD 4.13 billion in 2025. The region benefits from advanced pharmaceutical manufacturing facilities, strong regulatory enforcement, and substantial investments in quality assurance technologies.

Europe

Europe is projected to grow at a CAGR of 7.90% during the forecast period. Strong biologics manufacturing capabilities and established GMP standards continue to support regional growth.

Asia Pacific

Asia Pacific is expected to be the fastest-growing region, reaching USD 2.76 billion in 2026. Rapid pharmaceutical manufacturing expansion in China and India is driving increased investment in QC laboratories, contamination control systems, and regulatory compliance solutions.

Latin America and Middle East & Africa

These regions are anticipated to witness moderate growth due to increasing local pharmaceutical production, strengthening regulatory frameworks, and growing focus on reducing reliance on imported medicines.

Competitive Landscape

Leading companies operating in the pharma quality control and compliance market include:

  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Waters Corporation
  • Veeva Systems
  • Honeywell International Inc.
  • Sartorius AG
  • Charles River Laboratories
  • Eurofins Scientific
  • LabVantage Solutions Inc.
  • LabWare

These companies are focusing on integrated quality ecosystems, automation, cloud-based compliance solutions, and AI-enabled laboratory management platforms to strengthen their market positions.

Recent Industry Developments

  • January 2026: Charles River Laboratories announced plans to acquire PathoQuest to strengthen biologics testing and GMP quality control capabilities.
  • May 2025: Waters Corporation expanded Empower Software capabilities to support biologics QC analysis.
  • March 2025: LabVantage launched version 8.9 of its LIMS platform with AI-driven workflow enhancements.
  • March 2025: LabWare expanded its SaaS portfolio with LabWare ASSURE and LabWare QAQC solutions.
  • January 2025: Veeva and Zifo collaborated to accelerate quality control modernization through integrated LIMS solutions.

Conclusion

The pharma quality control and compliance market is poised for strong growth through 2034, driven by increasing pharmaceutical production, expanding biologics and advanced therapy pipelines, and stricter regulatory requirements worldwide. The growing adoption of automated compliance systems, cloud-based quality management platforms, and outsourced testing services is transforming the industry. While regulatory complexity and global supply-chain quality challenges remain significant concerns, continued investments in digital quality ecosystems, laboratory automation, and advanced compliance technologies will create substantial opportunities for market participants. As pharmaceutical companies focus on ensuring product safety, data integrity, and regulatory readiness, quality control and compliance solutions will remain a strategic priority across the global healthcare industry.

Segmentation By Offering, Application, Function, End User, and Region

By Offering * Products

    • Instruments
    • Consumables
  • Software
  • Services

By Application * Small Molecule Drugs

  • Biologics and Biosimilars
  • Vaccines
  • Cell and Gene Therapies
  • Others

By Function * Raw Material Quality Control

  • Microbiology and Contamination Control
  • Stability and Shelf-life Testing
  • In-process Quality Control
  • Finished Product Testing and Batch Release
  • Regulatory Compliance Management
  • Validation & Qualification / Quality Systems Management
  • Others

By End User * Pharmaceutical & Biotechnology Companies

  • CROs & CDMOs
  • Others

By Region * North America (By Offering, Application, Function, End User, and Country)

    • U.S.
    • Canada
  • Europe (By Offering, Application, Function, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Offering, Application, Function, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Offering, Application, Function, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Offering, Application, Function, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Technological Advancements in Pharma Quality Control and Compliance
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. New Product Launches, By Key Players
  • 4.4. Regulatory Scenario, By Key Countries/Regions

5. Global Pharma Quality Control and Compliance Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Offering
    • 5.1.1. Products
      • 5.1.1.1. Instruments
      • 5.1.1.2. Consumables
    • 5.1.2. Software
    • 5.1.3. Services
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Small Molecule Drugs
    • 5.2.2. Biologics and Biosimilars
    • 5.2.3. Vaccines
    • 5.2.4. Cell and Gene Therapies
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Function
    • 5.3.1. Raw Material Quality Control
    • 5.3.2. Microbiology and Contamination Control
    • 5.3.3. Stability and Shelf-life Testing
    • 5.3.4. In-process Quality Control
    • 5.3.5. Finished Product Testing and Batch Release
    • 5.3.6. Regulatory Compliance Management
    • 5.3.7. Validation & Qualification / Quality Systems Management
    • 5.3.8. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Pharmaceutical & Biotechnology Companies
    • 5.4.2. CROs / CDMOs
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Pharma Quality Control and Compliance Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Offering
    • 6.1.1. Products
      • 6.1.1.1. Instruments
      • 6.1.1.2. Consumables
    • 6.1.2. Software
    • 6.1.3. Services
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Small Molecule Drugs
    • 6.2.2. Biologics and Biosimilars
    • 6.2.3. Vaccines
    • 6.2.4. Cell and Gene Therapies
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Function
    • 6.3.1. Raw Material Quality Control
    • 6.3.2. Microbiology and Contamination Control
    • 6.3.3. Stability and Shelf-life Testing
    • 6.3.4. In-process Quality Control
    • 6.3.5. Finished Product Testing and Batch Release
    • 6.3.6. Regulatory Compliance Management
    • 6.3.7. Validation & Qualification / Quality Systems Management
    • 6.3.8. Others
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Pharmaceutical & Biotechnology Companies
    • 6.4.2. CROs / CDMOs
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Pharma Quality Control and Compliance Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Offering
    • 7.1.1. Products
      • 7.1.1.1. Instruments
      • 7.1.1.2. Consumables
    • 7.1.2. Software
    • 7.1.3. Services
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Small Molecule Drugs
    • 7.2.2. Biologics and Biosimilars
    • 7.2.3. Vaccines
    • 7.2.4. Cell and Gene Therapies
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Function
    • 7.3.1. Raw Material Quality Control
    • 7.3.2. Microbiology and Contamination Control
    • 7.3.3. Stability and Shelf-life Testing
    • 7.3.4. In-process Quality Control
    • 7.3.5. Finished Product Testing and Batch Release
    • 7.3.6. Regulatory Compliance Management
    • 7.3.7. Validation & Qualification / Quality Systems Management
    • 7.3.8. Others
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Pharmaceutical & Biotechnology Companies
    • 7.4.2. CROs / CDMOs
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Pharma Quality Control and Compliance Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Offering
    • 8.1.1. Products
      • 8.1.1.1. Instruments
      • 8.1.1.2. Consumables
    • 8.1.2. Software
    • 8.1.3. Services
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Small Molecule Drugs
    • 8.2.2. Biologics and Biosimilars
    • 8.2.3. Vaccines
    • 8.2.4. Cell and Gene Therapies
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Function
    • 8.3.1. Raw Material Quality Control
    • 8.3.2. Microbiology and Contamination Control
    • 8.3.3. Stability and Shelf-life Testing
    • 8.3.4. In-process Quality Control
    • 8.3.5. Finished Product Testing and Batch Release
    • 8.3.6. Regulatory Compliance Management
    • 8.3.7. Validation & Qualification / Quality Systems Management
    • 8.3.8. Others
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Pharmaceutical & Biotechnology Companies
    • 8.4.2. CROs / CDMOs
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Pharma Quality Control and Compliance Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Offering
    • 9.1.1. Products
      • 9.1.1.1. Instruments
      • 9.1.1.2. Consumables
    • 9.1.2. Software
    • 9.1.3. Services
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Small Molecule Drugs
    • 9.2.2. Biologics and Biosimilars
    • 9.2.3. Vaccines
    • 9.2.4. Cell and Gene Therapies
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Function
    • 9.3.1. Raw Material Quality Control
    • 9.3.2. Microbiology and Contamination Control
    • 9.3.3. Stability and Shelf-life Testing
    • 9.3.4. In-process Quality Control
    • 9.3.5. Finished Product Testing and Batch Release
    • 9.3.6. Regulatory Compliance Management
    • 9.3.7. Validation & Qualification / Quality Systems Management
    • 9.3.8. Others
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Pharmaceutical & Biotechnology Companies
    • 9.4.2. CROs / CDMOs
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Pharma Quality Control and Compliance Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Offering
    • 10.1.1. Products
      • 10.1.1.1. Instruments
      • 10.1.1.2. Consumables
    • 10.1.2. Software
    • 10.1.3. Services
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Small Molecule Drugs
    • 10.2.2. Biologics and Biosimilars
    • 10.2.3. Vaccines
    • 10.2.4. Cell and Gene Therapies
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Function
    • 10.3.1. Raw Material Quality Control
    • 10.3.2. Microbiology and Contamination Control
    • 10.3.3. Stability and Shelf-life Testing
    • 10.3.4. In-process Quality Control
    • 10.3.5. Finished Product Testing and Batch Release
    • 10.3.6. Regulatory Compliance Management
    • 10.3.7. Validation & Qualification / Quality Systems Management
    • 10.3.8. Others
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Pharmaceutical & Biotechnology Companies
    • 10.4.2. CROs / CDMOs
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of the Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Thermo Fisher Scientific Inc.
    • 11.2.2. Agilent Technologies, Inc.
    • 11.2.3. Waters Corporation
    • 11.2.4. Veeva Systems
    • 11.2.5. Honeywell International Inc.
    • 11.2.6. Sartorius AG
    • 11.2.7. Charles River Laboratories
    • 11.2.8. Eurofins Scientific
    • 11.2.9. LabVantage Solutions Inc.
    • 11.2.10. LabWare

List of Tables

  • Figure 1: Global Pharma Quality Control and Compliance Market Revenue Breakdown (USD billion, %) By Region, 2025 & 2034
  • Figure 2: Global Pharma Quality Control and Compliance Market Value Share (%), By Offering, 2025 & 2034
  • Figure 3: Global Pharma Quality Control and Compliance Market Value Share (%), By Application, 2025 & 2034
  • Figure 4: Global Pharma Quality Control and Compliance Market Value Share (%), By Function, 2025 & 2034
  • Figure 5: Global Pharma Quality Control and Compliance Market Value Share (%), By End User, 2025 & 2034
  • Figure 6: Global Pharma Quality Control and Compliance Market Value Share (%), By Region, 2025 & 2034
  • Figure 7: North America Pharma Quality Control and Compliance Market Value (USD billion), By Offering, 2025 & 2034
  • Figure 8: North America Pharma Quality Control and Compliance Market Value Share (%), By Offering, 2025
  • Figure 9: North America Pharma Quality Control and Compliance Market Value (USD billion), By Application, 2025 & 2034
  • Figure 10: North America Pharma Quality Control and Compliance Market Value Share (%), By Application, 2025
  • Figure 11: North America Pharma Quality Control and Compliance Market Value (USD billion), By Function, 2025 & 2034
  • Figure 12: North America Pharma Quality Control and Compliance Market Value Share (%), By Function, 2025
  • Figure 13: North America Pharma Quality Control and Compliance Market Value (USD billion), By End User, 2025 & 2034
  • Figure 14: North America Pharma Quality Control and Compliance Market Value Share (%), By End User, 2025
  • Figure 15: North America Pharma Quality Control and Compliance Market Value (USD billion), by Country, 2025 & 2034
  • Figure 16: North America Pharma Quality Control and Compliance Market Value Share (%), by Country, 2025
  • Figure 17: Europe Pharma Quality Control and Compliance Market Value (USD billion), By Offering, 2025 & 2034
  • Figure 18: Europe Pharma Quality Control and Compliance Market Value Share (%), By Offering, 2025
  • Figure 19: Europe Pharma Quality Control and Compliance Market Value (USD billion), By Application, 2025 & 2034
  • Figure 20: Europe Pharma Quality Control and Compliance Market Value Share (%), By Application, 2025
  • Figure 21: Europe Pharma Quality Control and Compliance Market Value (USD billion), By Function, 2025 & 2034
  • Figure 22: Europe Pharma Quality Control and Compliance Market Value Share (%), By Function, 2025
  • Figure 23: Europe Pharma Quality Control and Compliance Market Value (USD billion), By End User, 2025 & 2034
  • Figure 24: Europe Pharma Quality Control and Compliance Market Value Share (%), By End User, 2025
  • Figure 25: Europe Pharma Quality Control and Compliance Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Pharma Quality Control and Compliance Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Pharma Quality Control and Compliance Market Value (USD billion), By Offering, 2025 & 2034
  • Figure 28: Asia Pacific Pharma Quality Control and Compliance Market Value Share (%), By Offering, 2025
  • Figure 29: Asia Pacific Pharma Quality Control and Compliance Market Value (USD billion), By Application, 2025 & 2034
  • Figure 30: Asia Pacific Pharma Quality Control and Compliance Market Value Share (%), By Application, 2025
  • Figure 31: Asia Pacific Pharma Quality Control and Compliance Market Value (USD billion), By Function, 2025 & 2034
  • Figure 32: Asia Pacific Pharma Quality Control and Compliance Market Value Share (%), By Function, 2025
  • Figure 33: Asia Pacific Pharma Quality Control and Compliance Market Value (USD billion), By End User, 2025 & 2034
  • Figure 34: Asia Pacific Pharma Quality Control and Compliance Market Value Share (%), By End User, 2025
  • Figure 35: Asia Pacific Pharma Quality Control and Compliance Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Pharma Quality Control and Compliance Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Latin America Pharma Quality Control and Compliance Market Value (USD billion), By Offering, 2025 & 2034
  • Figure 38: Latin America Pharma Quality Control and Compliance Market Value Share (%), By Offering, 2025
  • Figure 39: Latin America Pharma Quality Control and Compliance Market Value (USD billion), By Application, 2025 & 2034
  • Figure 40: Latin America Pharma Quality Control and Compliance Market Value Share (%), By Application, 2025
  • Figure 41: Latin America Pharma Quality Control and Compliance Market Value (USD billion), By Function, 2025 & 2034
  • Figure 42: Latin America Pharma Quality Control and Compliance Market Value Share (%), By Function, 2025
  • Figure 43: Latin America Pharma Quality Control and Compliance Market Value (USD billion), By End User, 2025 & 2034
  • Figure 44: Latin America Pharma Quality Control and Compliance Market Value Share (%), By End User, 2025
  • Figure 45: Latin America Pharma Quality Control and Compliance Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Pharma Quality Control and Compliance Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Pharma Quality Control and Compliance Market Value (USD billion), By Offering, 2025 & 2034
  • Figure 48: Middle East & Africa Pharma Quality Control and Compliance Market Value Share (%), By Offering, 2025
  • Figure 49: Middle East & Africa Pharma Quality Control and Compliance Market Value (USD billion), By Application, 2025 & 2034
  • Figure 50: Middle East & Africa Pharma Quality Control and Compliance Market Value Share (%), By Application, 2025
  • Figure 51: Middle East & Africa Pharma Quality Control and Compliance Market Value (USD billion), By Function, 2025 & 2034
  • Figure 52: Middle East & Africa Pharma Quality Control and Compliance Market Value Share (%), By Function, 2025
  • Figure 53: Middle East & Africa Pharma Quality Control and Compliance Market Value (USD billion), By End User, 2025 & 2034
  • Figure 54: Middle East & Africa Pharma Quality Control and Compliance Market Value Share (%), By End User, 2025
  • Figure 55: Middle East & Africa Pharma Quality Control and Compliance Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Pharma Quality Control and Compliance Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 57: Global Pharma Quality Control and Compliance Market Share (%), by Company, 2025